Abstract Number: 0005 • ACR Convergence 2021
Maturation and Dysfunction of Autoreactive B Cell Clones in Tissues of Patients with Sjögren’s Syndrome
Background/Purpose: Sjögren's syndrome (SjS) involves chronic inflammation of exocrine glands that can be complicated by extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT). We…Abstract Number: 0321 • ACR Convergence 2021
Sequential Administration of Belimumab and Rituximab in Primary Sjögren’s Syndrome Reduces Minor Salivary Gland–Resident B Cells and Delays B-Cell Repopulation in Circulation
Background/Purpose: Primary Sjögren’s syndrome (pSS) is characterized by B-cell hyperactivity and elevated serum and saliva B-lymphocyte stimulator (BLyS) levels.1 Sequential administration of belimumab (BEL; anti-BLyS)…Abstract Number: 0416 • ACR Convergence 2021
Pharmacological Response of Rituximab Based on Dose Intensity in Maintenance Therapy of ANCA-Associated Vasculitis
Background/Purpose: Rituximab (RTX) has demonstrated efficacy in maintenance therapy in ANCA-associated vasculitis. However, different dosing protocols have been used in clinical trials and there is…Abstract Number: 0649 • ACR Convergence 2021
Optimizing SARS-CoV-2 Vaccine Timing in Rituximab-Treated Patients with Autoimmune Rheumatic Diseases: A Quality Improvement Intervention
Background/Purpose: Experience with rituximab (RTX) in autoimmune rheumatic disease (AIRD) has shown a clear association with hypogammaglobulinemia, serious infections, and impaired humoral response to certain…Abstract Number: 0964 • ACR Convergence 2021
Rituximab Treatment Dramatically Reduces Neutralizing Humoral Response to mRNA SARS-COV-2 Vaccines in Patients with Autoimmune Diseases
Background/Purpose: The global COVID-19 pandemic is starting to be controlled by massive vaccination. Some immunosuppressed patients have already paid a high price to the pandemic…Abstract Number: 1232 • ACR Convergence 2021
Synovial Tissue Lymphoid Aggregates Are Associated with Response to Rituximab Therapy in Rheumatoid Arthritis Patients
Background/Purpose: Activated B lymphocytes and plasma cells are implicated in the pathogenesis of rheumatoid arthritis (RA). The anti-CD20 monoclonal antibody therapy (Rituximab) is an effective…Abstract Number: 1445 • ACR Convergence 2021
Association Between Baseline Use of Rituximab and COVID-19 Outcomes in Patients with Rheumatoid Arthritis (RA)
Background/Purpose: Patients with Rheumatoid arthritis (RA) are at a potentially increased risk of SARS-CoV-2 infection, and immunosuppressive or biologic drugs used to treat RA might…Abstract Number: 1562 • ACR Convergence 2021
B Cell Reconstitution Is Strongly Associated with COVID-19 Vaccine Responsiveness in Rheumatic Disease Patients Treated with Rituximab
Background/Purpose: Rituximab (RTX) has previously been shown to impair antibody response to vaccines such as influenza and streptococcus. Recently, diminished COVID-19 vaccine responsiveness in RTX…Abstract Number: 008 • 2020 Pediatric Rheumatology Symposium
Incidence and Risk Factors of Hypogammaglobulinemia and Infectious Complications Associated with Rituximab Use in Pediatric Rheumatic Diseases
Background/Purpose: B-cell depletion therapy has increasingly been used for the treatment of childhood-onset rheumatic diseases. Previous studies investigating whether rituximab results in increased infections have…Abstract Number: 068 • 2020 Pediatric Rheumatology Symposium
Development of CARRA Consensus Treatment Plans for Severe ANCA-associated Vasculitis – Final CARRA-wide Consensus
Background/Purpose: Randomized trials for pediatric ANCA-associated vasculitis (ped-AAV) have not been feasible because of its rarity, therefore adult treatment strategies are usually adapted for children.…Abstract Number: 113 • 2020 Pediatric Rheumatology Symposium
Evaluation of B-cell Depletion with Rituximab and IVIG Concurrent Treatment in Pediatric Autoimmune Brain Disease
Background/Purpose: Rituximab is standard therapy in treating autoimmune brain disease (ABD) including refractory autoimmune encephalitis (AE) and Neuromyelitis Optica Spectrum Disease (NMOSD). Recommendations for continuing…Abstract Number: 143 • 2020 Pediatric Rheumatology Symposium
Immunological Profiles Following Treatment with Rituximab in Autoimmune Disease
Background/Purpose: Autoimmune diseases, including systemic lupus erythematosus (SLE), juvenile dermatomyositis (JDM), and Autoimmune Encephallitis (AE) arise due to dysregulation of the immune system and a…Abstract Number: 2634 • 2019 ACR/ARP Annual Meeting
ANCA Response upon Rituximab or Cyclophosphamide in ANCA-associated Vasculitis Patients
Background/Purpose: Recent studies have demonstrated that in patients with anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV) with successful remission-induction (RI) after cyclophosphamide (CYC), maintenance treatment with…Abstract Number: 2902 • 2019 ACR/ARP Annual Meeting
The Use and Safety of Rituximab in Connective Tissue Disease Associated Interstitial Lung Disease
Background/Purpose: Interstitial Lung Disease (ILD) is the most common lung manifestation in Connective Tissue Diseases (CTD). It is present in most types of CTD, such…Abstract Number: 2911 • 2019 ACR/ARP Annual Meeting
A Randomised, Open Labelled Clinical Trial to Investigate Synovial Mechanisms Determining Response – Resistance to Rituximab versus Tocilizumab in Rheumatoid Arthritis Patients Failing TNF Inhibitor Therapy
Background/Purpose: Although biologic therapies have transformed the outlook for rheumatoid arthritis (RA), the lack of a major treatment response in over 50% of patients, the…
- 1
- 2
- 3
- 4
- Next Page »